PORTAL

(redirected from portal hypertension)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.
Related to portal hypertension: ascites

PORTAL

A trading platform operated by NASDAQ of closely-held companies and other companies for investment by extremely high net-worth individuals. This market is largely exempt from the requirements of the Sarbanes-Oxley Act. In 2007, the Portal Market required an individual to have a minimum net worth of $100 million to qualify to trade on it.

PORTAL

A NASD trading system for unregistered foreign and domestic securities.
References in periodicals archive ?
All these patients were confirmed cases of cirrhosis so why there was no portal hypertension and in turn enlarged spleen.
Various criteria have been used to standardise the reporting of oesophageal varices as those compiled by the Japanese Research Society for Portal Hypertension, which include red colour signs, colour of the varix, form (size) of the varix and location of the varix.
Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
In this study, we found that the commonest cause of upper GI bleeding was portal hypertension (68.
Moreover, keep in mind that in terms of the level of liver disease, MELD is not prognostic in liver cancer-associated HPS patients, neither in metabolic diseases, portal hypertension syndromes, and any other clinical condition not directly associated to the extent of cirrhosis.
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response.
The gradual increase in the severity of portal hypertension was observed to be correlated with the deterioration of the endothelial functional condition in patients with alcoholic steatohepatitis [24].
The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
Transjugular intrahepatic portosystemic shunt for treatment of bleeding ectopic varices with portal hypertension.
This Phase 2 study, called the NASH-CX trial, is a multicentre, randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis.
It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects.